All-stock transactions will give Quanome approximately 5% stake in QAI Labs, the developer of NOVA-3, an AI-enabled platform designed for multi-specific antibody discovery

New York, Nov. 09, 2026 (GLOBE NEWSWIRE) — Quanome Technologies, Inc. (Nasdaq: QNME) (“Quanome” or the “Company”) today announced that it has entered into a definitive agreement, dated November 4, 2026, for its strategic investment in QAI Labs Ltd. (“QAI Labs” or “QAI”), an early-stage life sciences technology company developing NOVA-3, an AI-enabled discovery platform designed to combine quantum-computing algorithms (run on classical simulators) with laboratory testing to advance multi-specific antibody…